Kozbor D, Roder J C
Department of Microbiology and Immunology, Queen's University, Kingston, Ontario, Canada K7L 3N6.
Immunol Today. 1983 Mar;4(3):72-9. doi: 10.1016/0167-5699(83)90123-8.
Two conceptually unique approaches are currently available for the production of human monoclonal antibodies - the 'hybridoma' technique, based on the fusion of antibody-producing B lymphocytes with plasmacytoma cells or lymphoblastoid cell lines; and the use of Epstein-Barr virus (EBV) to 'immortalize' antigen-specific, human B lymphocytes. Here Danuta Kozbor and, John Roder discuss the contribution each technique is making, alone or in combination, towards the desired aim of producing human monoclonal antibodies with a defined specificity.
目前有两种概念上独特的方法可用于生产人单克隆抗体——“杂交瘤”技术，该技术基于产生抗体的B淋巴细胞与浆细胞瘤细胞或淋巴母细胞系的融合；以及使用爱泼斯坦-巴尔病毒（EBV）使抗原特异性人B淋巴细胞“永生化”。在这里，达努塔·科兹博尔和约翰·罗德讨论了每种技术单独或联合使用对生产具有明确特异性的人单克隆抗体这一预期目标所做的贡献。
